A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

NCT05075824 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Crovalimab
DRUG: Placebo

Sponsor

Hoffmann-La Roche